Turn Therapeutics Inc. filed a Current Report on Form 8-K on October 6, 2026, to furnish an updated investor presentation. The document details the company's pipeline, including the development of GX-03, a precision, non-systemic immunomodulation therapy, and outlines upcoming clinical milestones.
The presentation highlights GX-03, a first-in-class topical therapy targeting IL-36 and key downstream cytokines. The company reports that over 200,000 patients have received GX-03 with zero reported adverse events. The therapy is designed to be non-cytotoxic, non-sensitizing, and non-irritating.
Regarding clinical development, Turn Therapeutics is currently enrolling Stage 2 of a Phase 2 randomized controlled trial for moderate to severe Atopic Dermatitis (AD). The trial is designed with a sample size of approximately 120 to 135 patients and is powered to exceed 99.8%. The company anticipates topline results from this trial in the first quarter of 2027.
The presentation also outlines a broader development plan for GX-03, including a Phase 3 trial for AD expected to begin in mid-2027. Additionally, the company plans to initiate a Phase 3 trial for Onychomycosis (toenail fungus) in the second quarter of 2027 and a Phase 2a trial for Hidradenitis Suppurativa in the first quarter of 2027.
Turn Therapeutics also disclosed the out-licensing of its medical device assets, including FDA-cleared antimicrobial surgical gauze and sterile collagen powder, which are subject to $70 million in future milestones.
